Edition:
India

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

1.84USD
20 Jul 2018
Change (% chg)

$-0.02 (-1.08%)
Prev Close
$1.86
Open
$1.85
Day's High
$1.85
Day's Low
$1.84
Volume
38,737
Avg. Vol
95,283
52-wk High
$2.50
52-wk Low
$1.05

Latest Key Developments (Source: Significant Developments)

Scynexis Provides Corporate And SCY-078 Pipeline Update
Friday, 5 Jan 2018 

Jan 4 (Reuters) - Scynexis Inc ::SCYNEXIS PROVIDES CORPORATE AND SCY-078 PIPELINE UPDATE.SCYNEXIS INC - ‍INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078​.SCYNEXIS INC - ‍PLANS TO INITIATE A PHASE 2B STUDY OF SCY-078 IN INVASIVE CANDIDIASIS WITH LIPOSOMAL IV FORMULATION IN Q4 OF 2018​.SCYNEXIS - ‍ANTICIPATES DOSE REGIMEN SELECTED FROM DOVE STUDY TO BE SUBSEQUENTLY EVALUATED IN PHASE 3 STUDIES FOLLOWING END-OF-PHASE 2 MEETING WITH FDA​.  Full Article

Scynexis reports third quarter 2017 financial results
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Scynexis Inc :Scynexis reports third quarter 2017 financial results and provides company update.Q3 loss per share $0.31.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.  Full Article

SCYNEXIS says achieves new development milestones for SCY-078
Tuesday, 13 Dec 2016 

SCYNEXIS Inc : Pending discussions with FDA, plan to test in upcoming clinical trials of SCY-078 . Scynexis achieves new development milestones reinforcing versatility of SCY-078 in treating serious fungal infections .SCY-078 toxicology program was expanded to include three-month oral dose studies in two species.  Full Article

Scynexis enters into loan and security agreement with Solar Capital
Thursday, 6 Oct 2016 

Scynexis Inc : On September 30, 2016, Co entered into loan and security agreement with Solar Capital Ltd. - SEC filing .Solar providing Co with 48-month secured term loan of $15 million and all principal and accrued interest on term loan due on Sept 30, 2020.  Full Article

BRIEF-Scynexis Q1 Loss Per Share $0.12

* SCYNEXIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE